文献速递临床试验与 GCP

比较常规治疗、单靶点rTMS或双靶点rTMS治疗卒中后认知障碍的临床效果与神经科学洞见:随机对照试验研究方案

Comparing conventional treatment, single-target rTMS, or dual-target rTMS for the treatment of post-stroke cognitive impairment - clinical effects and neuroscientific insights: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-07-27

本研究为单中心、单盲随机对照试验,计划纳入57例卒中后认知障碍患者,随机分为三组,比较双靶点重复经颅磁刺激(rTMS)是否优于单靶点rTMS和常规治疗。主要结局为蒙特利尔认知评估北京版(MoCA-BJ)和简易精神状态检查(MMSE)测定的认知功能,所有结局在基线和治疗4周后测量。若双靶点rTMS显著改善认知功能,该方法可考虑作为卒中后认知障碍的一线临床治疗。

要点

  • 研究比较双靶点rTMS、单靶点rTMS与常规治疗对卒中后认知障碍的疗效。
  • 主要结局为MoCA-BJ和MMSE评估的认知功能,在基线和治疗4周后测量。
  • 若双靶点rTMS显著改善认知功能,作者认为可考虑作为一线临床治疗。

核心结论

  • 若双靶点rTMS显著改善认知功能,该方法可考虑作为卒中后认知障碍的一线临床治疗。
  • 本研究有望识别一种新的循证干预,以改善卒中后认知障碍患者的认知和独立生活能力。

研究设计与样本

  • 单中心、单盲、随机对照试验,计划招募57例卒中后认知障碍患者,按刺激部位随机分为三组。

主要发现

  • 主要结局为采用蒙特利尔认知评估北京版(MoCA-BJ)和简易精神状态检查(MMSE)测定的认知功能。
  • 次要结局为改良Barthel指数(MBI)、连线测验(TMT)和数字广度测验(DST)。
  • 通过经颅多普勒超声(TCD)检查及血清脑源性神经营养因子(BDNF)和血管内皮生长因子(VEGF)水平评估脑活动变化。
  • 所有结局在基线和治疗4周后测量。

临床怎么用

  • 作者认为,若双靶点rTMS显著改善认知功能,该方法可考虑作为卒中后认知障碍的一线临床治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although increasing evidence suggests that repetitive transcranial magnetic stimulation may help improve cognitive impairment after stroke, its clinical efficacy is still limited. This limitation may be due to the fact that the left dorsolateral prefrontal cortex (DLPFC) is only one of several brain areas involved in post-stroke cognitive impairment (PSCI). The aim of the present study is to reveal whether dual-target stimulation is superior to single-target stimulation and usual care in the treatment of PSCI. METHODS: A single-center, single-blind, randomized controlled trial will be conducted, and fifty-seven PSCI patients will be recruited and randomly assigned to one of three groups based on the stimulating site. The primary outcome is cognitive function, measured using the Montreal Cognitive Assessment Beijing Version (MoCA-BJ) and Mini-Mental Status Examination (MMSE). The secondary outcomes are the modified Barthel Index (MBI), Trail-Making Test (TMT), and digital span test (DST). Furthermore, changes in brain activity are assessed using transcranial Doppler sonography (TCD) examination and serum levels of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) closely related to nerve and vascular repair after brain injury. All outcomes will be measured at baseline and 4 weeks after treatment. DISCUSSION: If dual-target rTMS in significant improvements in cognitive function, this method could be considered as a first-line clinical treatment for PSCI. This proposed study has the potential to identify a new, evidence-based intervention that can enhance cognition and independent living in patients with cognitive impairment after stroke. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200066184 . It was registered on 26 November 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Xu B, Lin C, Guo C, et al. Comparing conventional treatment, single-target rTMS, or dual-target rTMS for the treatment of post-stroke cognitive impairment - clinical effects and neuroscientific insights: study protocol for a randomized controlled trial. Trials. 2023. PMID: 37501092. doi:10.1186/s13063-023-07491-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。